THIS PRODUCT ARE SHIPPED FROM EU ETA : 10-14 DAYS. IF YOU MIX WITH DOMESTIC US HUTECH LABS, THEN WE WILL SEND ALL FROM EU. IF YOU ONLY CHOOSE HUTECH LABS ETA IS 1-3 DAYS DOMESTIC ONLINE USA.
Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved TALZENNA® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced (LA) or metastatic breast cancer (MBC). Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor-positive (HR+) breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.
This approval follows the medicine’s approval by the U.S. Food and Drug Administration (FDA) in October 2018.
Only logged in customers who have purchased this product may leave a review.